Antibiotic resistance is a global concern. Globally, the use of antibiotics for treating bacterial infections is growing, especially in high-eukaryote regions. A common and potentially fatal antibiotic-resistant bacteria isE. coliorKlebsiellaspecies [
,
]. The resistance pattern is not always the same. It can vary from strain to strain and from organism to organism. The evolution of antibiotic resistance involves several steps. The first step is the selection of new bacterial strains by horizontal gene transfer (HGT) [
This can be achieved by the use of different mechanisms (i.e., efflux pumps, mobile genetic elements (MGEs) and horizontal gene transfer (HGT) [
]) [
The second step is the antibiotic resistance transformation (AR) [
] [
AR can be achieved in multiple ways. One way is by introducing antibiotic resistance genes into bacteria, such as plasmids, in the form of plasmids that are used for the production of resistance proteins [
In addition to the use of plasmids, another way is to introduce plasmids that are transformed into other organisms such as the bacteria, fungi and viruses [
A third way is the use of micro-organisms (MFs) to produce antibiotics. FBS is a natural polysaccharide that can be obtained from foods and can be used as a natural source of proteins [
FBS has been shown to be effective in the treatment of bacterial infections [
MFs are often used as a source of protein synthesis inhibitors [
The use of MFs has the potential to reduce the prevalence of antibiotic-resistant bacteria [
The MGFs can be divided into three groups: (i) the bacterial and mammalian MGFs; (ii) the bacterial MGFs from different species of the same genus; and (iii) the MGFs from different species that do not exhibit the same resistance pattern. In the next section, we will describe the uses of MGFs.
Metronidazole (MTZ) is a synthetic derivative of the naturally occurring nucleoside analog of pyrazole, which is a tetracycline antibiotic [
It has the activity of the well-known MTZ produced by the bacteriumMycobacterium tuberculosis(
) and the ability to inhibit the growth of
M. tuberculosisand
krakeniby inhibiting the synthesis of the
synthesis complex and the cell membrane. In addition, it has also been shown to inhibit the growth of
, as well as other aerobic bacteria [
However, the activity of MTZ in the presence of a high concentration of a synthetic peptide has not been reported. To investigate the effect of MGFs on the growth of
krakeni, MTZ was added to culture media ofand incubated at 37 °C. The culture broth (CBS) showed a growth promoting characteristic by the addition of the peptide of 1 g/L. The growth of the growth-promoting strain of
was significantly inhibited by addition of the peptide of 1 g/L. The inhibition of the growth of the growth-promoting strain of
was not detected after addition of the peptide of 1 g/L.
Common Name: Tetracycline HCl; Achromycin V
CAS Number: 64-75-5
Molecular Weight: 480.90
Chemical Formula: C22H24N2O8 • HCl
Solubility: Water
Storage Temperature: Room Temperature
Tetracycline hydrochloride is a hydrochloride salt form of the antibiotic tetracycline. This polyketide antibiotic binds to both the 30S and 50S ribosomal subunits, thus inhibiting proper protein synthesis. Although it is capable of binding to both subunits, the binding at the 30S subunit is more pronounced than that at the 50S. Clinically, tetracycline is used as a broad spectrum antibiotic for a variety of Gram-positive and Gram-negative bacterial infections. Conditions which may indicate for tetracycline administration include upper respiratory infection, typhus fever and rikkettsialpox. It can also be administered to treat severe cases of acne. Tetracycline has played a prominent research role in studies of the efficacy of local antibiotic application in cases of dental trauma. Owing to the fluorescent properties of tetracycline and its ability to bind to bone tissue, this antibiotic is also regularly used in bone histomorphometry studies.
Research or further manufacturing use only, not for food or drug use.
This medication is available in a easy-to-swallow tablet solution.Medical Professional Approval
This product is a rescue antibiotic. Generic antibiotics may not be as effective as their brand-name counterparts due to differences inmericities and chemical structure. Generic antibiotics may be used as a drug ingredient for emergency veterinary use only.Adherence
The content on this page is for informational purposes only. Please read our
page carefully before use.
This drug is a rescue antibiotic.Generic antibiotics may be used as a drug ingredient for rescue antibiotic only.| Packaging/Size | Strength |
|---|---|
| 50 mg | 10 mg |
| 100 mg |
Save16%
Original price$ 319.00
Current price$ 269.00
SKU23155-0767-01
Medical Professional License Required to Unlock Account(Note: We don’t Fill Personal Prescriptions)How to Order:
✔Send an email request to: [email protected]
You will receive instructions on how to create an account along with Rx Ordering Details.
Tetracycline HCl Capsules USP 500 mg is an antibiotic medication used to treat a variety of bacterial infections, including respiratory tract infections, skin infections, and urinary tract infections. It belongs to a class of antibiotics called tetracyclines, which work by preventing the growth and spread of bacteria. This medication should only be used to treat bacterial infections and will not work for viral infections such as the common cold or flu. Tetracycline HCl Capsules USP 500 mg is a prescription medication used to treat bacterial infections, including those involving the skin, respiratory tract, urinary tract, and digestive system. It can also be used to treat certain sexually transmitted infections and other conditions as determined by a doctor. The capsules are usually taken orally and the dosage and length of treatment will depend on the specific infection being treated. It is important to finish the full course of treatment prescribed by the doctor, even if the symptoms improve. It is important to take Tetracycline HCl Capsules USP 500 mg on an empty stomach (at least one hour before or two hours after meals) with a full glass of water. This medication should not be taken with dairy products, antacids, or iron supplements, as they can decrease the effectiveness of the medication. If the medication is being used to treat an infection, symptoms should start to improve within a few days. However, it is important to continue taking the medication for the prescribed length of time to ensure that the infection is fully treated and to prevent bacteria from becoming resistant to the antibiotic. If a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule should be resumed. Tetracycline HCl Capsules USP 50 mg may interact with other medications and supplements, so it is important to inform the doctor of any other medications being taken. It is also important to let the doctor know if there are any allergies to tetracycline or other antibiotics. Possible side effects of Tetracycline HCl Capsules USP 500 mg include nausea, vomiting, stomach upset, diarrhea, loss of appetite, and headache. If these side effects are severe or persistent, it is important to inform the doctor. If any serious side effects occur, such as difficulty breathing, yellowing of the skin or eyes, or symptoms of a severe allergic reaction, seek medical attention immediately. It is important to complete the full prescribed course of treatment for Tetracycline HCl Capsules USP 500 mg, even if symptoms improve, in order to fully eradicate the infection and prevent bacteria from becoming resistant to the medication.
Read More AboutIf you have been diagnosed with bacterial vaginosis (BV), endometritis, or mast cell disorders, BV may be an early sign of a new infection. It is estimated that if over 100,000 women in the United States are surviving with BV, they may experience more severe symptoms such as pain, nausea, and vomiting. It is important to note that BV does not affect sexual or reproductive health, and its symptoms are completely avoidable. However, BV may come as a welcome alternative. BV is defined as a clinical syndrome characterized by persistent and often disabling vaginal discharge, which is a natural state of the vagina that does not require treatment. It can sometimes progress to severe chronic conditions, such as pelvic inflammatory disease, inflammatory bowel disease, and Crohn’s disease. It is estimated that if over 100,000 women in the United States are surviving with BV, BV may occur as a new infection.
In the last decade, there has been a growing interest in the use of tetracyclines, particularly the tetracycline-resistant bacteria, in the treatment of diseases caused by the Gram-negative pathogens,. Tetracyclines are antimicrobial agents that work by inhibiting protein synthesis by binding to the bacterial 30S ribosome. They have broad-spectrum bactericidal activity against most Gram-positive and Gram-negative bacteria, includingandThey have anti-inflammatory and antibacterial activity against a wide range of gram-positive and gram-negative organisms. Tetracyclines are also effective in killing, both aerobic and anaerobic bacteria. They have a broad spectrum of activity against both aerobic and anaerobic bacteria.
In the United States, the Food and Drug Administration (FDA) reports that tetracyclines are associated with a 5% decrease in the rate of bacterial resistance to many antibiotics, compared to the placebo. This reduction in antibiotic use has resulted in the development ofin several countries, including the United States, Canada, and other developing countries. This risk is particularly high in Asia-Pacific, whereare prevalent. Tetracyclines are also associated with significant morbidity, including cardiovascular, respiratory, and gastrointestinal diseases.
In India, tetracyclines are associated with an increased risk of mortality and a higher incidence of gastrointestinal infections, especially in children. Tetracyclines are associated with a higher incidence of invasive and opportunistic infections in children, particularlyHowever, there is limited information on the use of tetracyclines for the treatment of infections caused byin children. This study sought to assess the risk of resistance to tetracyclines in Indian children, and to investigate the potential use of tetracyclines for the treatment of infections in children from India.
This prospective cohort study included participants aged 6–18 years, with a median age of 3.6 years, who were enrolled in a 3-armed outpatient clinic in a large metropolitan hospital in India. The study population was based on individuals residing in rural areas of the state of Maharashtra, India, with no access to hospital care or a pharmacy.
A total of 9,849 patients were enrolled in the study, of which 7,927 (66%) were from rural and 7,927 (66%) from urban areas of India. The study population was divided into two groups: those who were enrolled in the urban area and those who were enrolled in the rural area. Participants were randomly assigned to receive either a 0.5% or 5% dose of tetracycline in a 1-week, double-blind fashion. Patients were required to take the dose of the antibiotic for 14 days before they started the study. The study was conducted in accordance with the ethical principles set forth in the Declaration of Helsinki.
The study protocol was approved by the Research Ethics Committee of the University of Sari, India (Reference No. IS-10.08-08, 2017-05) and by the Research Ethics Committee of the Indian Institute of Health Research (Reference No. IS-10.08-01, 2017-06). The Institutional Review Board of the University of Sari, India, provided clearance for the study.
Study participants were enrolled in a 3-arm outpatient clinic in an urban metropolitan hospital, in an Indian metropolitan area. The study was conducted in accordance with the ethical principles set forth in the Declaration of Helsinki and the study was approved by the Institutional Review Board of the University of Sari, India, to obtain informed consent. Participants were enrolled in a prospective design. All participants underwent a screening questionnaire. The questionnaire contains information on the following five questions: (1) their demographic characteristics, such as age, gender, and race; (2) the symptoms of their disease, such as fever, vomiting, diarrhea, and pain; and (3) the symptoms of their infection, such as cough, sore throat, fever, and pain. The study was approved by the institutional review board and was registered in the ClinicalTrials.gov (number [NCT02375485](https://clinicaltrials.gov/ct2/show/NCT02375485) [NCT02375485](https://clinicaltrials.
Stade de France Pharmacy